Dexmedetomidine Use in Suprazygomatic Maxillary Nerve Blocks for Pediatric Adenotonsillectomy Pain Control

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The suprazygomatic maxillary nerve (SZMN) block is a well-established, safe and effective regional technique for pain management following cleft palate procedures. However, it has not been studied for patients undergoing tonsillectomy and adenoidectomy (T\&A) procedures. The goal of this study is to determine whether the SZMN block can be utilized to improve pain control and decrease morbidity in pediatric patients undergoing T\&A. An additional goal will be to determine whether the use of dexmedetomidine as a local anesthetic adjunct can prolong the analgesic effects of the SZMN block to cover the entire duration of pain experienced.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Maximum Age: 18
Healthy Volunteers: f
View:

• Ages 6 months - 18 years

• Give consent/parental consent to participate in study

• Patients undergoing tonsillectomy and adenoidectomy

Locations
United States
California
Lucile Packard Childrens Hospital
RECRUITING
Palo Alto
Contact Information
Primary
Ban CH Tsui, MD
bantsui@stanford.edu
(650) 200-9107
Backup
Ksenia Kasimova, MD
kasimova@stanford.edu
(650) 788-9458
Time Frame
Start Date: 2024-01-29
Estimated Completion Date: 2025-12
Participants
Target number of participants: 90
Treatments
Experimental: SZMN Treatment Group
Patients randomized into the SZMN treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic per side.
Experimental: SZMN+Dexmedetomidine Treatment Group
Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
No_intervention: No Intervention: Control Group
Patients in this group will receive the standard of care for T\&A procedures within the pediatric population.
Related Therapeutic Areas
Sponsors
Leads: Stanford University

This content was sourced from clinicaltrials.gov